Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call

Shalby Earnings Call: Key Takeaways

Shalby Limited delivered Q4 FY26 consolidated revenue growth of 9.4% YoY. Strategy focuses on diversifying specialties beyond arthroplasty and expanding the MedTech implant business.

Highlights
Revenue growth4.8% YoY for FY26; 9.4% YoY for Q4 FY26.
MarginsConsolidated EBITDA margin steady at 14.5% for FY26.
Demand visibilityStrong surgery counts in Oncology and Nephro-Urology segments.
Management confidenceHigh in 'Zero Technique' and multi-specialty diversification.

Growth

FY26 Consolidated Revenue reached ₹11,682 mn (up 4.8% YoY); PAT surged 1706% YoY to ₹347 mn due to tax regime adoption.

Outlook

Targeting 2200+ beds across 10 cities; focusing on doubling ROCE through operational leverage and asset-light O&M models.

Risks

International business (Delhi-NCR) reported EBITDA losses; hospital occupancy remains relatively low at 48%.

Source

Earnings Call filed with BSE, NSE: SHALBY. Summary written with AI assistance from the document.

Read the document ↗

Shalby Ltd: key numbers

Share price
₹147.12
Market cap
₹1,589 Cr
Revenue (annual)
₹1,141 Cr
Net profit (annual)
₹37.39 Cr
P/E (TTM)
40.4×Sector 57.8×
Promoter holding
74.33%+0.00% QoQ
FII holding
4.47%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Shalby Ltd

All →
15:09 IST NSE
Management Change

Shalby Management Change

Shareholders at the AGM did not approve the appointment of Mr. Shanay Vikram Shah as Director, resulting in his cessation from the Board effective September 10, 2026.

18:37 IST NSE
Annual General Meeting

Shalby Annual General Meeting

Shalby Limited held its 22nd Annual General Meeting on September 10, 2026. The meeting covered adoption of financial statements and appointment of a whole-time director.